IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Autores de IIS La Fe

• Juan Eduardo Megías Vericat

  Autor

• Octavio Antonio Ballesta López

  Autor

• Eva Barragán González

  Autor

• Pau Montesinos Fernández

  Autor

Grupos

• Farmacogenética

• Hematología y Hemoterapia

Abstract

The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 (IDH1(mut)), present in 7-14% of AML patients, have been discovered recently, opening the door to targeted agents aiming to improve the outcomes in this setting. Several oral selective IDH1(mut) inhibitors are under investigation, ivosidenib being the first approved for R/R AML. We performed a systematic review to analyze the clinical outcomes and safety reported with IDH1(mut) inhibitors and other agents in adult patients with IDH1(mut) R/R AML. Ivosidenib in monotherapy achieved complete remission (CR) of 24%, overall response of 42%, and median overall survival of 9 months in R/R AML, and promising outcomes were reported with IDH305 and FT-2102. IDH1(mut) inhibitors were generally well tolerated, but some therapy-related toxicities should be monitored, including IDH-differentiation syndrome, prolongation of the QT interval, and leukocytosis, all manageable and reversible. Also, venetoclax, CB-839, PARP inhibitors, and IDH1 peptide vaccine are being studied in IDH1(mut) AML. The results of the ongoing and upcoming clinical trials will bring new evidence to establish the role of IDH1(mut) inhibitors in therapeutic strategies of AML.

Keywords

• isocitrate dehydrogenase 1; acute myeloid leukemia; relapsed/refractory; ivosidenib; FT-2102; venetoclax